Advertisement
Advertisement
Pfizer
TOPIC
 / company

Pfizer

Pfizer
Pfizer
The latest news, analysis and opinion on Pfizer. In-depth analysis, industry insights and expert opinion.
Chairman / President
Albert Bourla
CEO / Managing Director
Albert Bourla
CFO / Finance Director
Dave Denton
Industry
Pharmaceuticals
Website
pfizer.com
Headquarters address
235 East 42nd Street, New York, NY 10017, United States
Stock Code
NYSE:PFE
Year founded
1849
LATEST China Science NEWS

How China’s ‘pig semen eyedrop’ may help deliver Alzheimer’s treatment

videocam
Pigs were chosen for the research because their tissue structure is similar to that of humans, and their supply is abundant. Photo: Shutterstock

‘Impossible for Chinese’: Yale scientist Zhang Kai leaves US for China

videocam
33
Zhang Kai has joined the University of Science and Technology of China in Hefei, Anhui province. Photo: Handout

How to take down a US F-35 over Iran? Chinese engineer’s tutorial goes viral

videocam
36
A US Marine Corps F-35C Lightning II lands on the flight deck of the USS Abraham Lincoln at an undisclosed location during Operation Epic Fury on March 7. Photo: US Navy/Planet Pix via ZUMA Press Wire/dpa

Is China’s commercial rocket now cheaper than Elon Musk’s SpaceX Falcon 9?

videocam
13
A Kinetica-2 Y1 carrier rocket, also known as the Lijian-2 Y1, with three satellites onboard blasts off from a launch centre in northwestern China on Monday. Photo: Xinhua

China’s far west site of a new bulwark against Mideast-induced resource woes

videocam
Construction has begun on the world’s largest coal-to-ethylene glycol project in Xinjiang’s Turpan prefecture, according to state media. Photo: CCTV
MORE China Science NEWS
The move will bring the total cumulative investment of Eli Lilly in China to nearly US$6 billion. Photo: Reuters
China’s private sector

Eli Lilly boosts China footprint with US$3 billion plan to expand supply chain

US firm is strengthening its China operations amid an intensifying expansion race with other pharmaceutical giants.

Medicine

‘Save a fortune’: Trump unveils TrumpRx discount drug site

Biomedicine: Industry Trends

China could approve first AI-designed drug next year, Merck executive says

Biomedicine: Industry Trends

Harbour BioMed stake in US drug developer shows Chinese firms’ growing clout

Latest example of Chinese drug maker acquiring equity in overseas partner shows they are becoming true development partners, analysts say.

Global drug companies no longer view Chinese firms as contract manufacturers, but as development partners, an analyst says. Photo: Shutterstock
Made in China 2025

Chinese biotechs strike a record US$136 billion in out-licensing deals in 2025

Chinese drug makers signed 157 out-licensing deals with global pharmaceutical firms last year versus 94 a year earlier.

Made in China 2025

Meow or never: China’s pudgy pets spark race for weight-loss drugs

Fosun and Huadong biotech labs eye feline obesity drugs as owners weigh cuteness against health risks.

Advertisement
Advertisement
Advertisement
United States

Are Chinese biotechs what the doctor ordered as Big Pharma faces ‘patent cliff’?

US drug makers are racing to plug looming ‘patent cliff’ revenue gaps – and increasingly they are turning to China biotechs.

US drugmakers are increasingly looking to Chinese biotechs as an answer to the revenue gaps left by the looming ‘patent cliff’. Illustration by Henry Wong
Made in China 2025

Chinese biotech Scizeng’s global licensing deal to yield up to US$1.44 billion

Yarrow Bioscience gets exclusive global rights for the GenSci098 therapy to treat thyroid eye disease and Graves’ disease.

Made in China 2025

China’s Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer

Yao Pharma’s deal with the US pharmaceutical giant underscores China’s growing role in global biotech licensing.

China economy

Opinion | How China engineered the rapid rise of its drug innovation industry

A market once dominated by generics is now an AI-powered pharmaceutical hub drawing billion-dollar investments from the likes of Pfizer and GSK.

videocam
A worker checks the position of a feeding tray in a pharmaceutical manufacturing facility at the Hengrui Biomedical Industrial Park in Lianyungang in Jiangsu province, on December 13, 2021. Photo: Getty Images
Science

Have Chinese chemists cracked the code for cheaper medicine production?

The research team’s straightforward alternative to expensive, complex and dangerous production method hailed as ‘Nobel Prize level’.

videocam
18
A study by researchers in China proposes an alternative to how medicinal compounds are traditionally made, which could make them cheaper to produce. Photo: AFP
US-China relations

Xi-Trump summit opens window of opportunity for US firms at China import expo

More US companies are expected at this year’s China International Import Expo, hoping to secure deals in wake of bilateral summit.

videocam
Hong Kong economy

Letters | How Hong Kong can help Chinese drug makers go global

Readers discuss opportunities from medical innovation, tech standards in Hong Kong, and how to stop people treating corals like inanimate objects.

Donald Trump

Trump says Pfizer will cut drug prices for tariff relief

The White House is also planning a direct-to-consumer website called TrumpRx for Americans to buy medication.

The Pfizer logo is pictured at company headquarters in Berlin in January 2021. Photo: dpa
Singapore

Singapore’s drug makers may be shielded from US tariffs: Deputy PM Gan

The city state may pursue a ceiling on tariff rates similar to deals that Washington has with other countries, Deputy PM Gan Kim Yong adds.

Singapore’s Deputy Prime Minister Gan Kim Yong addresses the US tariffs during a task force meeting in the city state in April. Photo: Reuters
Biomedicine: Companies

Pfizer’s Metsera acquisition to spur Chinese search for new weight drugs

The deal, worth up to US$7.3 billion, will encourage ongoing investment by mainland players but not draw in new rivals, analysts say.

Biomedicine: Companies

China’s Jiangsu Hengrui signs licensing deal with Braveheart Bio for heart drug

The licensing deal for the HRS-1893 innovative drug could fetch as much as US$1.01 billion in milestone payments.

Advertisement
Advertisement
Advertisement
Made in China 2025

China vows stronger biotech support as deals with global drug makers surge

Chinese developers signed one-third of all agreements with global drug firms in the first half of 2025.

Scientist using microscope for chemistry test samples. Photo: Shutterstock
Biomedicine: Companies

Pfizer, Chinese biotech firm 3SBio complete licensing deal for cancer drug

Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity investment in 3SBio.

European Union

EU chief Ursula von der Leyen easily survives parliament no-confidence vote

EU lawmakers dismissed allegations against Ursula von der Leyen regarding private text messaging with Pfizer’s CEO, misuse of funds, and election interference.

Singapore

Singapore prioritising pharmaceutical supply chains in US tariff talks

Pharmaceutical supply chains account for more than 10 per cent of Singapore’s exports to the US.

Photo: Shutterstock
CSPC Pharmaceutical

Chinese biotech’s mega drug-licensing deals with multinationals surge

Such deals allow Chinese firms to profit while minimising capital outlays, but also carry risks, law firm says.

Good mid-stage drug candidates from China at prices far below those in the US market are driving an increase in licensing deals, analysts say. Photo: Shutterstock
Biomedicine: Companies

Chinese biotech firm secures Pfizer deal despite trade tensions

Pfizer will produce the drug, which targets lung and colorectal cancers, in the US and take a US$100 million stake in China’s 3SBio.

videocam
European Union

EU’s von der Leyen loses court case over secret Pfizer texts

Wednesday’s ruling is likely to affect how the EU’s executive arm treats text messages in the future.

Biomedicine: Companies

Hong Kong residents reticent to get latest Covid-19 jab, Moderna survey finds

About 52 per cent of Hong Kong respondents said they were willing to get the updated vaccine, compared with 58 per cent in Singapore.

Moderna’s survey results indicate a “growing complacency” even as coronavirus variants continue to evolve. Photo: Shutterstock
Hong Kong healthcare and hospitals

Elderly Hongkongers can apply for Covid XBB variant vaccine starting Wednesday

Elderly residents can go to community vaccination stations run by private clinics or designated general outpatient clinics under Hospital Authority.

The first batch of 100,000 doses of the XBB mRNA vaccine manufactured by BioNTech and Pfizer arrived in Hong Kong in late November. Photo: Sam Tsang
Hong Kong healthcare and hospitals

Hong Kong receives first batch of Covid XBB variant vaccines

Vaccination arrangements for the 100,000-jab batch manufactured by US drug firm Pfizer expected to be announced in December.

5
Hong Kong healthcare and hospitals

Hong Kong’s private healthcare sector expected to offer RSV vaccine in December

British pharmaceutical company GSK beats Pfizer in race to offer vaccine that can protect elderly against common respiratory infection.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement